The earnings call reflected strong financial performance with significant revenue and profit growth, expansion into new markets, and progress in the vitiligo program. However, increased expenses, competitive challenges, and a disconnect between market valuation and company performance were notable concerns.

Company Guidance -

Q4 2025

In the recent CLINUVEL investor webinar, the company reported robust financial performance for the half-year ending December 31, 2024, with several key metrics highlighted. Sales increased by 10.5% to AUD 36 million, and total revenues rose by 21% to AUD 43 million. Expenses were well-contained, growing by only 2%, leading to a substantial 48% rise in profit before tax, reaching nearly AUD 22 million, and a 30% increase in profit after tax to AUD 14 million. Earnings per share climbed by 27%, from AUD 0.22 to AUD 0.28. The balance sheet showed a 7% increase in net assets, and cash reserves grew by 8% to AUD 198 million. The company remains debt-free for the 20th consecutive year, emphasizing its commitment to self-funding expansion initiatives and maintaining cost controls while executing its vitiligo program. The strategic focus remains on building long-term shareholder value while navigating competitive pressures and leveraging its unique distribution model.

Strong Revenue and Profit Growth

Sales grew by 10.5% to $36 million, total revenues increased by 21% to $43 million, profit before tax rose by 48% to just under $22 million, and profit after tax increased by almost 30% to $14 million. Earnings per share rose by 27% from $0.22 to $0.28 per share.

Balance Sheet Strength

Net assets increased by 7% and cash reserves rose by 8% to $198 million. The company remains debt-free for the 20th consecutive year.

Operational Expansion

Increased revenues from more patients being treated and higher dosing frequency. Expansion into new jurisdictions such as Canada and Latin America and growth of prescriber network to 93 sites in North America.

Vitiligo Program Development

Successful engagement with medical community and visible repigmentation seen in clinical trials. The company's model has been effectively applied to vitiligo.

Clinuvel Pharmaceuticals (CLVLF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CLVLF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 28, 2025	2025 (Q4)	0.18 / -	0.318	―	―	―
Feb 26, 2025	2025 (Q2)	0.14 / 0.18	0.136	32.08% (+0.04)
Aug 29, 2024	2024 (Q4)	0.28 / 0.32	0.244	30.34% (+0.07)
Feb 21, 2024	2024 (Q2)	0.17 / 0.14	0.141	-3.64% (>-0.01)	―
Aug 29, 2023	2023 (Q4)	0.24 / 0.24	0.196	24.67% (+0.05)	―
Feb 22, 2023	2023 (Q2)	0.20 / 0.14	0.073	92.98% (+0.07)	―	―
Aug 30, 2022	2022 (Q4)	0.20 / 0.20	0.23	-14.85% (-0.03)	―	―
Feb 22, 2022	2022 (Q2)	0.15 / 0.07	0.082	-10.24% (>-0.01)	―	―
Aug 26, 2021	2021 (Q4)	- / 0.23	0.203	12.97% (+0.03)	―	―
Feb 23, 2021	2021 (Q2)	- / 0.08	0.014	504.76% (+0.07)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CLVLF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 26, 2025	$6.95	$6.95	0.00%
Aug 29, 2024	$9.40	$10.43	+10.96%
Feb 21, 2024	$10.55	$9.85	-6.64%
Aug 29, 2023	$13.55	$12.68	-6.42%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Clinuvel Pharmaceuticals Limited (CLVLF) report earnings?

Clinuvel Pharmaceuticals Limited (CLVLF) is schdueled to report earning on Aug 28, 2025, TBA (Confirmed).

What is Clinuvel Pharmaceuticals Limited (CLVLF) earnings time?

Clinuvel Pharmaceuticals Limited (CLVLF) earnings time is at Aug 28, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CLVLF EPS forecast?

CLVLF EPS forecast for the fiscal quarter 2025 (Q4) is 0.18.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing